



BLA 125293/S-083

**SUPPLEMENT APPROVAL  
REMS MINOR MODIFICATION APPROVAL**

Crealta Pharmaceuticals LLC  
500 W. Silver Spring Drive, Suite K-200  
Glendale, WI 53217

Attention: John André  
Senior Director, Regulatory Affairs

Dear Mr. André:

Please refer to your Supplemental Biologics License Application (sBLA), dated June 5, 2015, received June 5, 2015, submitted under section 351(a) of the Public Health Service Act for Krystexxa (pegloticase) Injection, 8 mg/mL.

We acknowledge receipt of your amendment dated July 21, 2015.

This Changes Being Effected supplemental biologics application provides for proposed modifications to the approved risk evaluation and mitigation strategy (REMS).

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for Krystexxa (pegloticase) was originally approved on September 14, 2010, and the most recent modification was approved on October 10, 2013. The REMS consists of a communication plan and a time table for submission of assessments of the REMS. Your proposed modifications to the REMS consist of changes to the REMS document and the

appended REMS materials to replace all references to the previous applicant Savient Pharmaceuticals, Inc. with Crealta Pharmaceuticals LLC.

Your proposed modified REMS, submitted on June 5, 2015, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS remains the same as that approved on October 10, 2013.

There are no changes to the REMS assessment plan described in our September 14, 2010, letter.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any of goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A). This assessment should include:

- a) An evaluation of how the benefit-risk profile will or will not change with the new indication;
- b) A determination of the implications of a change in the benefit-risk profile for the current REMS;
- c) *If the new, proposed indication for use introduces unexpected risks:* A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
- d) *If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* A statement about whether the REMS was meeting its goals at the time of that the last assessment and if any modifications of the REMS have been proposed since that assessment.
- e) *If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use:* Provision of as many of the currently listed assessment plan items as is feasible.
- f) *If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including:* Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS. *If you are not proposing a REMS modification, provide a rationale for why the REMS does not need to be modified.*

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment

instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**BLA 125293 REMS CORRESPONDENCE**  
**(insert concise description of content in bold capital letters, e.g.,**  
**UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT**  
**METHODOLOGY**

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**BLA 125293 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR BLA 125293/S-000**  
**CHANGES BEING EFFECTED IN 30 DAYS**  
**PROPOSED MINOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR BLA 125293/S-000**  
**PRIOR APPROVAL SUPPLEMENT**  
**PROPOSED MAJOR REMS MODIFICATION**

*or*

**NEW SUPPLEMENT FOR BLA 125293/S-000**  
**PRIOR APPROVAL SUPPLEMENT**  
**PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABEL CHANGES**  
**SUBMITTED IN SUPPLEMENT XXX**

**NEW SUPPLEMENT (NEW INDICATION FOR USE)**  
**FOR BLA 125293/S-000 REMS ASSESSMENT**

**PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

**REMS REVISION FOR BLA 125293**

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

If you do not submit electronically, please send 5 copies of REMS-related submissions.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Carol F. Hill, Senior Regulatory Health Project Manager for Safety, at (301) 796-1226.

Sincerely,

*{See appended electronic signature page}*

Sally Seymour, MD  
Deputy Director for Safety  
Division of Pulmonary, Allergy, and Rheumatology  
Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE:  
REMS

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SALLY M SEYMOUR  
07/30/2015